World Vaccine Congress Investor Panel, April 4th “…..Mr Carthy commented that “antigen specific tolerance has the potential to deliver disease modifying therapy for indications including autoimmune, allergies and protein drug antibody reactions. AnTolRx has...
Dr. Francisco J Quintana will be presenting data on AnTolRx's antigen-specific nanoparticle platform. Join us in Boston April 24-26, 2018. http://as-immunetolerance.com
We are excited to attend the 36th annual JP Morgan Healthcare Conference in San Francisco, CA from January 8th-11th, 2018.